RNA polymerase III subunit GGenealiases: C31 · RPC32 · RPC7
Q-omics provides the consensus-scored POLR3G profile across patient tissues and cancer cell-line models. POLR3G expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, POLR3G is differentially expressed in 14, with the highest sampling consensus in KIRP. Additionally, POLR3G RNA expression shows 19,156 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, KIRP, and UVM as cancer lineages where POLR3G shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POLR3G — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POLR3G survival associations across molecular data types. POLR3G RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POLR3G RNA expression–survival associations across cancer types. High POLR3G expression shows unfavorable associations in BLCA, KICH, MESO, KIRC, KIRP and UVM. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for POLR3G RNA expression.
This table summarizes POLR3G tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRP for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for POLR3G. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POLR3G shows higher tumor expression in KIRP, COAD, LUSC, BLCA, LUAD and HNSC. The KIRP box plot shows higher POLR3G RNA expression in tumor versus normal tissue (log2 FC = +0.456, t-test p < 0.001).
This table shows molecular features associated with POLR3G in patient tissues and cancer cell lines. In patient samples, POLR3G shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, POLR3G RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
